LONDON--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced that the European Medicines Agency has authorized an update to the Summary of Product Characteristics (SmPC) for Baxter's ...
Deerfield, Ill., July 25, 2003 -- Baxter Healthcare Corporation announced today that the U.S. Food and Drug Administration (FDA) has approved ADVATE (Antihemophilic Factor (Recombinant), ...
Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method] for routine prophylaxis ...
ADVATE (antihemophilic factor [recombinant] plasma/albumin-free method) 4000IU for IV use by Baxter Baxter announced that the FDA has approved a new 4000 IU dosage strength of Advate (Antihemophilic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results